Published on
April 27, 2026
- 11:00 GMT
ISHA Therapeutics Receives U.S. FDA QIDP Designation for ISHA-004 for the Treatment of Oropharyngeal Candidiasis
HILLSBOROUGH TOWNSHIP, NJ, UNITED STATES, April 27, 2026 /EINPresswire.com/ -- ISHA Therapeutics LLC, a company focused on advancing therapies through the 505(b)(2) regulatory pathway, today announced that the U.S. Food and Drug Administration (FDA) has …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
